Literature DB >> 596974

Cytosine arabinoside binding to human plasma proteins.

H C van Prroijen, G Vierwinden, J Wessels, C Haanen.   

Abstract

The interaction of cytosine arabinoside (Ara-C) with human plasma proteins was investigated by means of ultrafiltration and ultracentrifugation. The results obtained with both methods did not differ significantly. Ara-C binding was studied at plasma levels within the therapeutic range (0.005-1.0 mg/l). It appeared that 13.3% (SD: 2.2%) of Ara-C in the plasma was bound to proteins. The percentage of bound drug was independent of the drug concentration, at least in the therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 596974

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  5 in total

1.  Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.

Authors:  S Lindemalm; J Liliemark; B S Larsson; F Albertioni
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 2.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study.

Authors:  Verena Schöning; Charlotte Kern; Carlos Chaccour; Felix Hammann
Journal:  Front Pharmacol       Date:  2022-02-09       Impact factor: 5.810

4.  A radioimmunoassay for cytosine arabinoside.

Authors:  E M Piall; G W Aherne; V M Marks
Journal:  Br J Cancer       Date:  1979-10       Impact factor: 7.640

5.  Relationship between protein binding and extravascular drug concentrations of a water-soluble drug, cytosine arabinoside.

Authors:  M L Slevin; A Johnston; R C Woollard; E M Piall; T A Lister; P Turner
Journal:  J R Soc Med       Date:  1983-05       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.